profenid 100 mg tabletki powlekane
sanofi winthrop industrie - ketoprofenum - tabletki powlekane - 100 mg
profenid 200 mg tabletki o przedłużonym uwalnianiu
sanofi-aventis france - ketoprofenum - tabletki o przedłużonym uwalnianiu - 200 mg
bi-profenid 150 mg tabletki o zmodyfikowanym uwalnianiu
sanofi winthrop industrie - ketoprofenum - tabletki o zmodyfikowanym uwalnianiu - 150 mg
profenid 100 mg czopki
sanofi winthrop industrie - ketoprofenum - czopki - 100 mg
dimethyl fumarate neuraxpharm
laboratorios lesvi s.l. - fumaran dimetylu - stwardnienie rozsiane, Рецидивно-znika - leki immunosupresyjne - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
tecfidera
biogen netherlands b.v. - fumaran dimetylu - stwardnienie rozsiane - leki immunosupresyjne - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
dimethyl fumarate mylan
mylan ireland limited - fumaran dimetylu - stwardnienie rozsiane, Рецидивно-znika - leki immunosupresyjne - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate polpharma
zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - fumaran dimetylu - stwardnienie rozsiane, Рецидивно-znika - leki immunosupresyjne - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate teva
teva gmbh - fumaran dimetylu - multiple sclerosis, relapsing-remitting; multiple sclerosis - leki immunosupresyjne - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
dimethyl fumarate accord
accord healthcare s.l.u. - fumaran dimetylu - multiple sclerosis, relapsing-remitting; multiple sclerosis - leki immunosupresyjne - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).